An observational study in Melanoma Stage IV and Melanoma Stage III, sponsored by Pierre Fabre Pharma GmbH. Recruiting at 59 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-19.
Sponsored by Pierre Fabre Pharma GmbH (part of Pierre Fabre) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 284 studies in Melanoma with a site in Germany — 37 open to participants now, 70 under way, 20 of them phase 3. Melanoma · Germany.
Among the 284 studies in Melanoma with a site in Germany, this one is the 12th largest by planned enrollment of the 32 observational ones that give a count, is one of 11 that started in 2019, is one of 32 observational ones, reaches primary completion later than 24 of the 69 other live ones, and was the 201st registered.
3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.
Browse Melanoma studies →37 of the 284 studies in Melanoma with a site in Germany are open now. Recruiting first, the newest first:
Charite University, Berlin, Germany · Sites in Germany
Ages 18+
Bristol-Myers Squibb · Sites in Germany, United States, Belgium and 10 more countries
Ages 18+
Wuerzburg University Hospital · Sites in Germany
Ages 18+
Kupando GmbH · Sites in Germany
Ages 18+
Mitra Bio · Sites in Germany, Belgium, Spain and 1 more country
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
284 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 78 · Phase 2 124 · Phase 3 75 · Phase 4 3
First in 1995; this study’s year is marked. 11 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 750 is above the median of 187 across 489 observational studies indexed under Melanoma.
Median enrollment 162 across the 249 interventional studies, 420 across the 32 observational. Of the 183 that completed or were terminated, 90 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
202 of 284 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pierre Fabre Pharma GmbH, one of the names counted as Pierre Fabre. Under that name alone:
Pierre Fabre Pharma GmbH is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Pierre Fabre has 9 studies filed under Melanoma — fewer than ten, so there is no comparison to draw.
20 of the studies in Melanoma with a site in Germany that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05608291Phase 3Regeneron PharmaceuticalsA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | 2027-01-15 |
| NCT05987332Phase 3IDEAYA BiosciencesIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | 2027-01-15 |
| NCT05270044Phase 3Pierre Fabre MedicamentAdjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. | 2027-03-31 |
| NCT04309409Phase 3University Hospital, EssenAdjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma | 2027-09 |
| NCT06112314Phase 3Immunocore LtdIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) | 2027-10-16 |
Add all 20 to your calendar (.ics) → With an account.
Among the 284 studies in Melanoma with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
BERING-MELANOMA - designed as a prospective, longitudinal, non-interventional study - investigates real-world effectiveness, quality of life, safety and tolerability of encorafenib plus binimetinib in unresectable advanced or metastatic BRAF(Rapidly Accelerated Fibrosarcoma isoform B)-V600-mutant malignant melanoma after commercial availability of these two products in Germany, Austria and Switzerland. The study focusses on the documentation of the first and second line setting (i.e. after one line of prior checkpoint inhibition) by documenting patients treated according to the SmPC (Summary of Product Characteristics).
Adult patients with unresectable advanced or metastatic BRAFV600-mutant malignant melanoma, with a decision to receive targeted treatment with Encorafenib/Binimetinib according to the current SmPC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Previous treatment with a BRAF- and/or MEK [Mitogen-Activated Protein/Extracellular-signal Regulated Kinase]- inhibitor except for:
-- prior treatment with BRAF+MEK-inhibitor combination therapy that ended > 6 months prior start of Encorafenib/Binimetinib treatment;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Observation of real-life treatment with encorafenib and binimetinib
Observation of real-life treatment with encorafenib and binimetinib
Progression-free survival
Progression-free survival rate
Time frame: At 12 months after start of treatment
Patient and disease profiles at start of treatment with encorafenib plus binimetinib
Demographic and disease characteristics
Time frame: Baseline
Type of treatments before and after encorafenib plus binimetinib
Treatment sequence prior to and after encorafenib plus binimetinib; by documenting pre-treatments with adjuvant therapy and systemic therapy in palliative setting; and by documenting subsequent systemic treatment lines after administration of encorafenib plus binimetinib
Time frame: Complete observation time-frame (the total observation period of this study will amount to 90 months).
Sequence of treatments before and after encorafenib plus binimetinib
Treatment sequence prior to and after encorafenib plus binimetinib; by documenting pre-treatments with adjuvant therapy and systemic therapy in palliative setting; and by documenting subsequent systemic treatment lines after administration of encorafenib plus binimetinib
Time frame: Complete observation time-frame (the total observation period of this study will amount to 90 months).
Characteristics of treatment with encorafenib plus binimetinib
Evaluation of reason for treatment selection (efficacy, safety profile, quality of life, patients preference, physician's preference, comorbidities, other)
Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)
Effectiveness of treatment with encorafenib plus binimetinib
Further progression-free survival parameters
Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)
Effectiveness of treatment with encorafenib plus binimetinib
Time-to-progression
Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)
Effectiveness of treatment with encorafenib plus binimetinib
Best observed tumor response
Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)
Effectiveness of treatment with encorafenib plus binimetinib
Overall response rate
Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)
Effectiveness of treatment with encorafenib plus binimetinib
Duration of response
Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)
Effectiveness of treatment with encorafenib plus binimetinib
Disease control rate
Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)
Effectiveness of treatment with encorafenib plus binimetinib
Duration of disease control
Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)
Effectiveness of treatment with encorafenib plus binimetinib
Overall survival
Time frame: Complete observation time-frame (the total observation period of this study will amount to 90 months).
Patient reported outcomes during treatment with encorafenib plus binimetinib - evaluated with EORTC QLQ C-30
EORTC QLQ C-30 questionnaires (European Organisation for Research and Treatment of Cancer Quality of Life C-30 questionnaires) to assess quality of life of cancer patients; comprises 30 items, 24 of which are aggregated into nine multi-item scales, that is, five functioning scales (physical, role, cognitive, emotional and social), three symptom scales (fatigue, pain and nausea/vomiting) and one global health status scale. The remaining six single-item (dyspnoea, appetite loss, sleep disturbance, constipation, diarrhoea and the financial impact) scales assess symptoms.
Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)
Patient reported outcomes during treatment with encorafenib plus binimetinib evaluated with WPAI
WPAI questionnaires (Work Productivity and Activity Impairment questionnaires). The following questions ask about the effect of patients melanoma on the ability to work and perform regular activities. 1. Are you currently employed (working for pay)? 2. During the past seven days, how many hours did you miss from work because of problems associated with your melanoma? 3. During the past seven days, how many hours did you miss from work because of any other reason? 4. During the past seven days, how many hours did you actually work? 5. During the past seven days, how much did your melanoma affect your productivity while you were working? 6. During the past seven days, how much did your melanoma affect your ability to do your regular daily activities, other than work at a job?
Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)
Patient reported outcomes during treatment with encorafenib plus binimetinib evaluated with CTSQ
CTSQ questionnaires (Cancer Therapy Satisfaction Questionnaire) to assess patients' opinions and feelings concerning their cancer therapy and associated adverse events: 1. Questions to patients thoughts about cancer therapy (IV/pills). Scale: \[Always, Most of the time, Some-times, Rarely, Never\]; 2. Questions to patients satisfaction with the most recent cancer therapy (IV/pills): 1. Scale reg. benefit: \[Much better than my expectations Somewhat better than my expectations, Met my expectations, Somewhat worse than my expectations, Much worse than my expectations\]; 2. Scale reg. side effects: \[Much better than I expected, Somewhat better than I expected, Exactly as I expected, Somewhat worse than I expected, Much worse than I expected\]; 3. Scale reg. satisfaction: \[Very satisfied, Satisfied, Neither satisfied nor dissatisfied, Dissatisfied, Very dissatisfied\]; 4. Scale reg. choice of therapy: \[Yes, definitely, Probably Yes, I don't know, Probably not, Definitely not\]
Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)
Physicians' satisfaction with regard the treatment with encorafenib plus binimetinib
Physicians' satisfaction questionnaires (measuring Physician's Satisfaction with regard to Effictiveness and Safety, as well as Physician's Overall Treatment Satisfaction) using the following scale construct: 1. Physician's Satisfaction with regard to Efficiency 2. Physician's Satisfaction with regard to Safety 3. Physician's Overall Treatment Satisfaction Scale: * very dissatisfied * dissatisfied * moderately satisfied * satisfied * very satisfied
Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)
Safety and tolerability of treatment with encorafenib plus binimetinib - Adverse events and adverse reactions including time to onset and time to resolution
Number of patients with Adverse Events and maximum grade per patient, Adverse Drug Reactions, Adverse Drug Reactions grade 3/4, Serious Adverse Events, Serious Adverse Drug Reactions.
Time frame: Complete observation time-frame (the total observation period of this study will amount to 90 months).
Prognostic factors
Influence of prognostic factors on quality of life outcome parameters
Time frame: Complete observation time-frame (the total observation period of this study will amount to 90 months).
Prognostic factors
Influence of prognostic factors on effectiveness
Time frame: Complete observation time-frame (the total observation period of this study will amount to 90 months).
Prognostic factors
Influence of prognostic factors on safety
Time frame: Complete observation time-frame (the total observation period of this study will amount to 90 months).
Treatment duration
From date of first treatment (encorafenib or binimetinib, whichever occurs first) until date of last treatment (encorafenib or binimetinib, whichever occurs last)
Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)
Treatment dose intensity
From date of first treatment (encorafenib or binimetinib, whichever occurs first) until date of last treatment (encorafenib or binimetinib, whichever occurs last)
Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)
Number of treatment interruptions
From date of first treatment (encorafenib or binimetinib, whichever occurs first) until date of last treatment (encorafenib or binimetinib, whichever occurs last)
Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)
Duration of treatment interruptions
From date of first treatment (encorafenib or binimetinib, whichever occurs first) until date of last treatment (encorafenib or binimetinib, whichever occurs last)
Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2019 (actual). Primary completion is estimated for Dec 2026, 86 months after the start.
Of 59 industry-sponsored observational studies under Melanoma, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 80. This study's planned 86 months is above that.
Counting every sponsor, half of 236 studies reached it within 71 months; a quarter within 35 and three quarters within 248.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.